Fox Chase Cancer Center News

Fox Chase Cancer Center and Fox Chase – Temple Urologic Institute Physician Joshua Cohn to Serve as Consultant to Shriners Children’s Philadelphia

PHILADELPHIA (February 13, 2024) — As part of a recently announced collaboration, Joshua Cohn, MD, FPMRS, an Associate Professor in the Department of Urology at Fox Chase Cancer Center and a member of the Fox Chase – Temple Urologic Institute, will serve as a consultant at Shriners Children’s Philadelphia. He will care for patients with neurogenic urologic conditions, in which a patient lacks bladder control due to injury, neurological disorders, or congenital malformations.
VIEW STORY

Fox Chase Cancer Center Welcomes Yash Chhabra

PHILADELPHIA (February 9, 2024) — Fox Chase Cancer Center is pleased to announce the hiring of Yash Chhabra, PhD, as an Assistant Professor in the Cancer Signaling and Microenvironment Research Program, where he will focus on the influence of sex disparity in cancer and aging.
VIEW STORY

New Fox Chase Study Finds Immunotherapy Effective for Both Black and White Patients With Metastatic Renal Cell Carcinoma

PHILADELPHIA (January 26, 2024) — While race can influence treatment recommendations for certain forms of cancer, a new study presented today by researchers at Fox Chase Cancer Center has shown that immune checkpoint inhibitor-based treatment (ICI), a type of immunotherapy, is an equally effective frontline treatment for both Black and white patients with metastatic renal cell carcinoma.
VIEW STORY

Nursing Researchers at Fox Chase Cancer Center and Temple Health Receive $564,000 Grant to Increase Clinical Trial Enrollment of Underrepresented Kidney Cancer Patients

PHILADELPHIA (January 24, 2024) — A team of nursing researchers from Fox Chase Cancer Center and Temple Health has received a $564,000 grant from the U.S. Department of Defense to fund research into increasing clinical trial enrollment of underrepresented kidney cancer patients by making it easier for them to participate in such trials.
VIEW STORY